Recognized as a Great Place to Work| Takeda Philippines

Takeda Healthcare Philippines, a leading biopharmaceutical company, has been recognized as a Great Place to Work® for the second year in a row. Based on the Trust Index survey, 100% of Takeda employees believe that the company is an excellent place to work, surpassing the average of 53% for global companies. This achievement reflects Takeda's strong commitment to creating an exceptional working environment and its dedication to excellence.

In addition, 100% of employees at Takeda Healthcare Philippines, Inc. have collectively expressed that they see management as honest and ethical in their business practices, they feel good about the ways they contribute to the community, and they are proud to be part of the company.

Loreann Villanueva, Country Manager of Takeda Philippines, expressed her pride in the company's culture and the unwavering dedication of its employees. “Being certified as a Great Place to Work is an important recognition for Takeda Philippines. It is a testament to how our leaders & employees strive to create a positive impact in our organization that is anchored on trust, transparency and collaboration. Our amazing company culture is built on a solid foundation that allows our employees to make values-based decisions to bring to life our mission of providing better health and a brighter future in the Philippines."

“This certification further inspires us and our employees to continue delivering our purpose of broadening access to our innovative medicines to the Filipino patients. It is also an acknowledgment that the work that we do every day and the meaning behind every decision we make are driven and led by employees who are fully committed, passionate and engaged,” she added.

Takeda Healthcare Philippines not only prioritizes patients' access to medicines and quality treatment but also places great importance on creating a diverse and inclusive organization where employees can thrive and reach their full potential. The company is committed to fostering an honest and ethical workplace environment.

To promote a healthy and holistic working environment, Takeda Philippines offers various initiatives for its employees ranging from non-work related activities that fosters mutual trust and friendship, to trainings, mentoring programs and workshops to promote employee growth and holistic development.

The company has also adopted a hybrid work arrangement for their employees and a strict “no-meeting Fridays.” These efforts intend to deliberately give employees the work-life balance they need as well as to provide flexibility through streamlined work schedules and processes.

Takeda Healthcare Philippines' commitment to its employees and the community has garnered recognition beyond the Great Place to Work® certification. The company also ranked 8 in the small business category of the Philippines’ Best Workplaces 2023. It was also recognized as a Top Employer in the Philippines by the Top Employers Institute.

Takeda Philippines is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a global R&D-driven biopharmaceutical company. Its headquarters in Makati City are home to Takeda Philippines’ employees who all share the same passion, drive, and commitment towards delivering life-transforming treatments, and sustainable patient access programs.

To learn more about Takeda and its initiatives, please visit www.takeda.com.

About Takeda

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

Takeda Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient access to treatment across the country through sustainable access programs enabling affordable and integrated access solutions for disease areas such as oncology, gastroenterology, rare diseases & vaccines and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.

For more information, visit https://www.takeda.com.

Media Contacts

Takeda Philippines

• Arabella Benito - [email protected]

COMCO Southeast Asia

• Ferdinand Bondoy - [email protected]

• Joyce Yu - [email protected]

• Pinky Tuason – [email protected]

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.